Leukemia and Lymphoma Unit

Leukemia and Lymphoma Unit

Our Leukemia and Lymphoma Unit provides diagnosis, clinical care and research relating to leukemias, lymphomas and other hematologic cancers such as myeloma, myelodysplasia and Hodgkin’s disease. Our diagnostic tests for these conditions include chromosome and molecular analysis, flow cytometry and expert hematologic pathology services.

Our patients are treated using the best conventional approaches as well as clinical trials of the newest therapies.  Recently pioneered therapeutic approaches to these diseases at UC San Diego include gene therapy for leukemia, novel vaccine therapies and new monoclonal antibodies, and the latest approaches to stem cell transplantation.

For more information on individual cancer types — including symptoms, risk factors, diagnosis, and treatment information — see the links below:

Care Team

Although a cancer diagnosis can be frightening, there are many new therapies and potential cures for cancers of the blood and lymphatic system. At UC San Diego Moores Cancer Center, our internally recognized specialists will develop a treatment plan designed for you.

Clinical Trials 

In recent years, researchers have made remarkable progress in the battle against all types of cancer. To learn about current clinical trials for our patients, see Clinical Trial Search.

In addition, UC San Diego is one of seven sites collaborating in the CLL Research Consortium (CRC), which runs clinical trials for patients with chronic lymphocytic leukemia. View CRC trials or learn more about the CRC.

Blood Cancer Research Fund

The Blood Cancer Research Fund (BCRF) concentrates on developing cures for all types of blood-related cancers. Its research labs are located here at Moores Cancer Center, and its director is Dr. Thomas Kipps of UC San Diego. Learn more about the Blood Cancer Research Fund.

Appointments

For more information or to make an appointment:

Moores Cancer Atrium 

Contact the Leukemia and Lymphoma Unit

Appointments: 866-773-2703


Subscribe to Our Newsletter